E-LIB Suche - Ergebnisse für: Symeonidis, A.

1

87P Real-world evidence of FTD/TPI and bevacizumab combinat..:

Koumarianou, A. ; Ntavatzikos, A. ; Symeonidis, D....
Annals of Oncology. 35 (2024) - p. S42-S43 , 2024

Link: https://doi.org/10.1016/..

2

REAL‐LIFE EXPERIENCE WITH RITUXIMAB‐DOSE‐ADJUSTED EPOCH (R‐..:

Vassilakopoulos, T. ; Ferhanoglu, B. ; Horowitz, N....
Hematological Oncology. 41 (2023) S2 - p. 410-411 , 2023

Link: https://doi.org/10.1002/..

3

Topic: AS04-MDS Biology and Pathogenesis/AS04h-Immune dereg..:

Chatzilygeroudi, T. ; Chondrou, V. ; Athanasopoulou, K....
Leukemia Research. 128 (2023) - p. 107216 , 2023

Link: https://doi.org/10.1016/..

4

TREATMENT STRATEGIES AND PROGNOSTIC FACTORS FOR THE OUTCOME..:

Vassilakopoulos, T. P. ; Liaskas, A. ; Rizzuto, G....
Hematological Oncology. 41 (2023) S2 - p. 677-677 , 2023

Link: https://doi.org/10.1002/..

5

P1178: THE APPLICABILITY OF PROGNOSTIC MODELS UNDER RITUXIM..:

Vassilakopoulos, Theodoros ; Ferhanoglu, B ; Horowitz, Na...
HemaSphere. 7 (2023) S3 - p. e2522583 , 2023

Link: https://doi.org/10.1097/..

6

P1229: RITUXIMAB-DOSE-ADJUSTED EPOCH (R-DA-EPOCH) IN PRIMAR..:

Vassilakopoulos, T. ; Ferhanoglu, B. ; Horowitz, N. A....
HemaSphere. 6 (2022) - p. 1114-1115 , 2022

Link: https://doi.org/10.1097/..

7

P16: DARATUMUMAB MONOTHERAPY HAS A FAVORABLE EFFECT ON BONE..:

Terpos, E ; Ntanasis-Stathopoulos, I ; Kastritis, E...
HemaSphere. 6 (2022) - p. 20-20 , 2022

Link: https://doi.org/10.1097/..

8

S168: ERYTHROPOIETIN STIMULATION AGENTS SIGNIFICANTLY IMPRO..:

Garelius, H. ; Smith, A. ; Bagguley, T....
HemaSphere. 6 (2022) - p. 69-70 , 2022

Link: https://doi.org/10.1097/..

9

P1646: PRIMARY IMMUNE THROMBOCYTOPENIA (ITP) IN PATIENTS OL..:

Pontikoglou, C. ; Matheakakis, A. ; Stavroulaki, E....
HemaSphere. 6 (2022) - p. 1527-1528 , 2022

Link: https://doi.org/10.1097/..

10

Lipid and lipoprotein profile of patients with multiple mye..:

Hatziri, A. ; Lazaris, V. ; Symeonidis, A..
Atherosclerosis. 331 (2021) - p. e125 , 2021

Link: https://doi.org/10.1016/..

11

Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome a..:

Silzle, T. ; Taylor, A. ; De Witte, T....
Leukemia Research. 108 (2021) - p. 106679.4 , 2021

Link: https://doi.org/10.1016/..

12

ISATUXIMAB PLUS CARFILZOMIB AND DEXAMETHASONE IN PATIENTS W..:

Maiolino, A ; Hajek, R ; Jelinek, T...
Hematology, Transfusion and Cell Therapy. 43 (2021) - p. S197-S198 , 2021

Link: https://doi.org/10.1016/..

13

RITUXIMAB‐DOSE‐ADJUSTED EPOCH (R‐DA‐EPOCH) IN PRIMARY MEDIA..:

Vassilakopoulos, T. ; Ferhanoglu, B. ; Horowitz, N....
Hematological Oncology. 39 (2021) S2 - p. , 2021

Link: https://doi.org/10.1002/..

14

ISATUXIMAB PLUS POMALIDOMIDE AND DEXAMETHASONE IN PATIENTS ..:

Capra, M.E.Z. ; Beksac, M. ; Richardson, P.G....
Hematology, Transfusion and Cell Therapy. 42 (2020) - p. 263-264 , 2020

Link: https://doi.org/10.1016/..

15

Assessment of HDL functionality in newly diagnosed multiple..:

Hatziri, A. ; Lazaris, V. ; Symeonidis, A..
Atherosclerosis. 315 (2020) - p. e150 , 2020

Link: https://doi.org/10.1016/..